(Supplement Fig. 31) In a pan-cancer analysis, SLC7A5 reflects several biological characteristics of TME, such as antitumor immunity, immunogenicity and cancer stemness, which is expected to be a predictor of ICB treatment response and tumor prognosis. Here, SLC7A5 is linked to cancer.